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Background: The first documented case of Middle East Respiratory Syndrome coronavirus (MERS-CoV) occurred in
2012, and outbreaks have continued ever since, mainly in Saudi Arabia. MERS-CoV is primarily diagnosed using a
real-time RT-PCR assay, with at least two different genomic targets required for a positive diagnosis according to
the case definition of The World Health Organization (WHO) as of 3 July 2013. Therefore, it is urgently necessary to
develop as many specific genetic diagnostic methods as possible to allow stable diagnosis of MERS-CoV infections.
Methods: Reverse transcription-loop-mediated isothermal amplification (RT-LAMP) is a genetic diagnostic method
used widely for the detection of viral pathogens, which requires only a single temperature for amplification, and
can be completed in less than 1 h. This study developed a novel RT-LAMP assay for detecting MERS-CoV using
primer sets targeting a conserved nucleocapsid protein region.
Results: The RT-LAMP assay was capable of detecting as few as 3.4 copies of MERS-CoV RNA, and was highly
specific, with no cross-reaction to other respiratory viruses. Pilot experiments to detect MERS-CoV from medium
containing pharyngeal swabs inoculated with pre-titrated viruses were also performed. The RT-LAMP assay exhibited
sensitivity similar to that of MERS-CoV real-time RT-PCR.
Conclusions: These results suggest that the RT-LAMP assay described here is a useful tool for the diagnosis and
epidemiologic surveillance of human MERS-CoV infections.
Keywords: Meddle East respiratory syndrome (MERS), MERS coronavirus (MERS-CoV), RT-LAMP, Genetic diagnostic
methodBackground
On 22 September 2012, a novel coronavirus sequence
was detected from a 49-year-old patient presenting with
severe pneumonia who was initially treated in an inten-
sive care unit in Qatar and then moved to London [1].
The sequence of the PCR amplicon of this isolate was a
close match with that of a coronavirus isolated from a
60-year-old patient who had died of severe pneumonia
in Jeddah, Saudi Arabia in June 2012 [1,2]. Together,
these two cases marked the beginning of an outbreak of* Correspondence: shirato@nih.go.jp
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unless otherwise stated.severe respiratory infections caused by a newly identi-
fied coronavirus, designated the Middle East Respiratory
Syndrome coronavirus (MERS-CoV) [3]. This outbreak
is ongoing, with 836 confirmed cases to date that have
resulted in 288 deaths in 19 countries (Jordan, Qatar,
Saudi Arabia, the United Arab Emirates, Oman, Kuwait,
Yemen, Lebanon, Iran, Algeria, Tunisia, France, the
Netherlands, Germany, the United Kingdom, Greece,
Malaysia, Philippines and the United States of America)
as of 14 July, 2014 [The World Health Organization
(WHO), Global Alert and Response (GAR), Coronavirus
infections, updated on 14 July 2014, http://www.who.
int/csr/disease/coronavirus_infections/en/index.html].
Sequence analyses show that MERS-CoV clusters with
the group 2c betacoronavirus, and is closely related toLtd. This is an Open Access article distributed under the terms of the Creative
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respiratory syndrome coronavirus (SARS-CoV), which
caused severe pneumonia resulting in 8,098 reported in-
fections and 774 deaths between 2002 and 2003 [5], was
also derived from bat coronaviruses [6,7]. MERS-CoV,
with its similar symptoms and phylogeny, is therefore con-
sidered a cousin of SARS-CoV. The reservoir for MERS-
CoV remains unclear, but recent reports suggest that
camels are the most likely candidate, as a form of the
virus has been circulating in camels in Saudi Arabia
since at least 1992 [8-13].
MERS-CoV is primarily diagnosed using a real-time
RT-PCR assay, and at least two different genomic targets
are required for a positive diagnosis. The first probe and
primer sets for MERS-CoV detection by real-time PT-
PCR were developed by Corman et al. shortly following
the first reports of the disease [14,15]. Among them, the
probe and primer sets targeting upE and ORF1a exhibit
the highest sensitivities, and remain the most widely
used targets for MERS-CoV detection. At least two dif-
ferent specific genomic targets are required for a positive
diagnosis according to the case definition announced by
the WHO as of 3 July 2013 [WHO, GAR, Revised inte-
rim case definition for reporting to WHO – Middle East
respiratory syndrome coronavirus (MERS-CoV), updated
on 3 July 2013, http://www.who.int/csr/disease/corona
virus_infections/case_definition/en/index.html]. A single
positive target followed by gene sequencing is also con-
sidered positive; however, the current gene sequencing
technique requires PCR amplicons, and the ability of
conventional RT-PCR to produce a sequencing-quality
template is generally lower than that of real-time RT-
PCR [16-20]. Therefore, it is urgently necessary to
develop as many specific genetic diagnostic methods
as possible to allow reliable diagnosis of MERS-CoV
infections.
The loop-mediated isothermal amplification (LAMP)
method amplifies specific nucleic acid sequences using a
set of four or six unique primers [21,22]. The LAMP
procedure is user-friendly, since the reaction mixture is
incubated at a single temperature for less than 1 h.
Amplification can be detected as the precipitation of
magnesium pyrophosphate or by fluorescence under
ultra-violet light, and also can be detected in real time
by monitoring the turbidity of the pyrophosphate [23].
The LAMP assay can also be used for the detection of
RNA by combining reverse transcription with LAMP
(RT-LAMP) [21]; RT-LAMP assays have been developed
for a variety of respiratory RNA viruses, including SARS
[24], respiratory syncytial virus [25,26], and influenza vi-
ruses [27,28]. In this study, a novel RT-LAMP method
for the detection of MERS-CoV was developed, with a
sensitivity similar to that of real-time RT-PCR targeting
upE and ORF1a.Materials and methods
Viruses
The MERS-CoV EMC isolate was kindly provided by
Ron A. M. Fouchier, Erasmus Medical Center, Rotterdam,
The Netherlands. MERS-CoV was propagated and titrated
using Vero cells. Human respiratory syncytial viruses
(RSV; Long, A2, B WV/14617/85 and 18537) were ob-
tained from the American Tissue Culture Collection
(ATCC). Human metapneumovirus (HMPV; Sendai-H/
2404/2003) was obtained from the Virus Research Cen-
ter, Sendai Medical Center, Japan. Human coronavirus
(HCoV)-229E isolates ATCC VR-740 and Sendai-H/1121/
04 [29] were used. HCoV-NL63 was supplied by Dr. Hoek,
University of Amsterdam, Netherlands. Isolate HCoV-
OC43 was obtained from ATCC. SARS coronavirus
(Frankfurt strain) was supplied by Dr. J. Ziebuhr, Uni-
versity of Würzburg, Germany. Human parainfluenza
viruses (PIV) 1 (strain C35) and 3 (strain C243) were
obtained from ATCC. Adenoviruses (ADV) (serotype
3, strain G.B.; serotype 4, strain RI-67; and serotype
7, strain Gomen) were obtained from ATCC. Viruses
were propagated and titrated using HEp-2, HeLa, RD,
Vero cells, or LLC-Mk2 cells [30]. Influenza viruses
[Flu; A/California/7/2009 (H1N1pdm), A/Victoria/210/
2009 (H3N2), and B/Brisbane/60/2008] were provided
by the Influenza Virus Research Center of the National
Institute of Infectious Diseases in Japan, and were pro-
pagated and titrated using MDCK cells.
Design of primer sets for RT-LAMP
Primer sets for the RT-LAMP assay were designed using
the online LAMP primer design software (PrimerExplorer
V4; http://primerexplorer.jp/e/) based on the nucleocap-
sid protein sequence of the EMC isolate of MERS-CoV
(GenBank JX869059.2).
Extraction of nucleic acids
RNA was extracted from viral stocks using TRIzol LS or
TRIzol reagent (Invitrogen), according to the manufac-
turer’s instructions. Viral DNA was extracted using Qiagen
Genomic-tip (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. Total RNA and genomic DNA
were quantitated using standard methods to measure the
OD value. The MERS-CoV RNA copy number was cal-
culated based upon the standard curve obtained using a
TaqMan assay, as described by Corman et al. [14] (upE
probe set and the positive control template). Total RNA
was then diluted with ribonuclease-free water containing
10 μg/mL of Ribonucleic Acid from Baker’s Yeast (R6750;
Sigma-Aldrich, St. Louis, MO, USA) as carrier RNA.
RT-LAMP assay
The RT-LAMP assay was performed using the Loopamp
RNA Amplification Kit (RT-LAMP; Eiken, Tokyo, Japan)
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DNA) was mixed with 40 pmol each of FIP and BIP
primers, 20 pmol each of LF and LB primers, 5 pmol each
of F3 and B3 primers, 1-μL Enzyme Mix, and 12.5-μL Re-
action Mix; distilled water was added to obtain a final vol-
ume of 25 μL. For real-time monitoring of RT-LAMP
amplification, the reaction mixture was incubated at 65°C
for 30 min in a Loopamp real-time turbidimeter (LA-
320C, Eiken). For fluorescence detection, 1-μL Fluorescent
Detection Reagent (Eiken) was added to the reaction mix-
ture described above before the start of amplification, and
then, fluorescence was detected under ultraviolet light
after 30 min of amplification. Negative controls containing
only yeast RNA were included in each assay.
To synthesize control RNA for RT-LAMP, the nucleo-
capsid protein sequence of the EMC strain (28566–
29807) was amplified and cloned into the pGEM-T easy
vector (Promega, Fitchburg, WI, USA). Point mutations
were inserted using a site-direct mutagenesis technique
to generate variations of the nucleoprotein sequence.
The nucleocapsid protein sequence was amplified by
PCR using forward (5′-TAATACGACTCACTATAGG
GATGGCATCCCCTGCTGCACC-3′) and reverse (5′-
CTAATCAGTGTTAACATCAA-3′) primers with Pri-
meSTAR Max DNA polymerase (Takara-Bio, Shiga,
Japan). The amplicons were gel-purified and were used
as templates for RNA transcription using a MEGAscript
T7 Transcription Kit (Life Technologies, Carlsbad, CA,
USA). The transcribed RNA was quantified using the
OD value, the copies number was calculated, and the
RNA was diluted with ribonuclease-free water contain-
ing 10 μg/mL of yeast RNA.
Real-time RT-PCR assays
Real-time RT-PCR assays using upE and ORF1a sets
[14,15] were also performed for virus detection using a
QuantiTect Probe RT-PCR kit (QIAGEN) and LightCycler
480 Instrument (Roche, Basel, Switzerland) following the
manufacturers’ protocols. The amplification conditions
followed Corman et al. [14,15].
Virus preparation for spiked samples
For sensitivity assays, Vero cells were infected with MERS-
CoV, and incubated for 4 days. Cell supernatants were then
collected and centrifuged at 1,500 × g for 30 min at 4°C,
and the supernatants were treated with RNaseA (Nippon-
gene, Tokyo Japan) at a concentration of 10 μg/mL for
30 min at 37°C to exclude miscellaneous RNA other than
viral RNA.
Pilot experiment
MERS-CoV RNA was obtained from pre-titrated viral
stocks diluted with medium containing pharyngeal swabs
obtained from healthy adults using the Universal ViralTransport for Viruses, Chlamydiae, Mycoplasmas and
Ureaplasmas (Becton Dickinson and Company, Sparks,
MD, USA). Viral isolation was also performed on Vero
and Vero/TMPRSS2 cells constitutively expressing type II
transmembrane serine protease (TMPRSS2) [30], which
enhances cell entry and fusion formation of MERS-CoV
[31,32]. Diluted viruses were inoculated on Vero and
Vero/TMPRSS2 cells, and incubated for 60 min. Cells
were then washed with PBS, and incubated in Dulbecco’s
modified Eagle’s medium supplemented with 5% fetal calf
serum at 37°C. The cytopathic effect was evaluated 5 days
after inoculation. Clinical specimens (nasopharyngeal
swabs) diagnosed as other respiratory pathogens by RT-
PCR assays were used as negative controls. Informed,
written consent was obtained at the time of sample collec-
tion from all patients. For the specimen diagnosed as hu-




The primer sets used in this study are listed in Table 1.
RT-LAMP requires at least six specific sequences (F1,
F2, F3, B3, B2, and B1), targeted by a minimum of four
distinct primer sets. Two loop primers (LF and LB) are
used to enhance amplification [22]; these primers target
the regions between F1 & F2, and B1 & B2 regions, re-
spectively. Generally, the reaction of RT-LAMP is per-
formed for 1 h. However, the primers described here
tend to generate products of self-construction because
these were constructed to enhance the sensitivity of amp-
lification. Therefore, the reaction was performed within
30 min to exclude non-specific reactions. It was confirmed
that non-specific amplification did not take place within
30 min using negative control samples (data not shown).
Sensitivity and specificity of the RT-LAMP assay
The detection limit of the RT-LAMP assay was deter-
mined using serially diluted MERS-CoV, and compared
with those of real-time RT-PCR using upE and ORF1a
assays [14,15] (Table 2). upE and ORF1a assays were able
to detect 1.6 to 3.4 copies of MERS-CoV RNA, consist-
ent with previous reports. The threshold for RT-LAMP
within 30 min was also 3.4 copies, indicating a sensitivity
equivalent to that of real-time RT-PCR [14,15].
RT-LAMP amplification can be monitored in three
DNA contamination-free manners. First is a real-time
method that monitors the turbidity of the pyrophosphate
precipitation using a turbidimeter (LA-320C) (Figure 1a).
The differentiated value of each signal is calculated auto-
matically at the same time during amplification, with
values > 0.1 considered positive. RT-LAMP can also de-
tect MERS-CoV without any specific instruments by
detecting visible signals at the same level as real-time
Table 1 The primer set for MERS-CoV RT-LAMP assay
Primers Position (EMC, JX869059.2) Sequence (5′ – 3′) Number of matched MERS sequences*
F3 28848–28866 GCTCCCAGGTGGTACTTCT 86/88
B3 29061–29042 cagtcccctcaatgtggaag 88/88
FIP (F1c + F2) 28939–28918 tcatggacccaaacgatgccatACTGGAACTGGACCCGAAG 77/88
+ 28872–28890 88/88
BIP (B1c + B2) 28956–28977 GCTCCTTCAACTTTTGGGACGCtagtaccgggcgcgaatt 87/88
+ 29028–29011 83-88
LF 28906–28891 cggaatgggagtgctg 88/88
LB 28978–29000 GGAACCCTAACAATGATTCAGCT 85/88
Capital letters indicate the sense strand; lowercase letters indicate the antisense strand.
*Eighty-one sequences were obtained from GenBank (JX869059, KJ829365, KJ813439, KJ713299, KJ713298, KJ713297, KJ713296, KJ713295, KJ650297, KJ650296,
KJ650295, KJ650098, KJ556336, KJ477102, KJ156953, KJ156952, KJ156949, KJ156944, KJ156942, KJ156939, KJ156934, KJ156932, KJ156927, KJ156917, KJ156916,
KJ156913, KJ156911, KJ156910, KJ156909, KJ156907, KJ156906, KJ156905, KJ156902, KJ156901, KJ156883, KJ156881, KJ156876, KJ156874, KJ156873, KJ156872,
KJ156871, KJ156869, KJ156866, KJ156865, KJ156862, KJ156861, KF961222, KF961221, KF958702, KF917527, KF811035, KF745068, KF600652, KF600651, KF600647,
KF600645, KF600644, KF600643, KF600639, KF600636, KF600635, KF600634, KF600632, KF600630, KF600628, KF600627, KF600623, KF600621, KF600620, KF600613,
KF600612, KF192507, KF186567, KF186566, KF186565, KF186564, KC875821, KC776174, KC667074, KC164505, and KJ782550) and seven sequences were obtained
online (England2-HPA, http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317138176202: Jeddah_2014_C7149, C7569, C7770, C8826, C9055, and C9355,
http://www.virology-bonn.de/index.php?id=46).
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visual detection of magnesium pyrophosphate precipi-
tation following completion of the reaction (Figure 1b).
Furthermore, amplicons can be detected by means of
green fluorescence under ultraviolet light by adding a
fluorescence detection reagent to the mixture before the
start of amplification (Figure 1c).
In addition to MERS-CoV, specific amplification via
RT-LAMP was also tested using various respiratory vi-
ruses (Table 3). RT-LAMP was performed using pre-
titrated viral stocks, as well as clinical specimens pre-
viously validated by PCR. MERS-CoV RT-LAMP was
specific for MERS-CoV; other respiratory viruses, such
as HCoV, SARS-CoV, RSV, influenza, PIV, ADV, and
HMPV could not be amplified using the MERS-CoV
primers.
Pilot experiments
As MERS-CoV clinical isolates are not available in Japan,
a pilot study was performed using MERS-CoV labora-
tory isolates diluted with medium containing pharyngeal
swabs obtained from healthy adults. Viral detection was
carried out using both RT-LAMP and real-time RT-PCR
assays, and with virus isolation using Vero and Vero/Table 2 Sensitivity of the RT-LAMP assay
Copies/reaction 500,000 50,000 5000 500 50
Real-time RT-PCR*
upE 21.2 24.4 27.9 31.3 34.
ORF1a 21.6 24.4 27.6 30.4 32
RT-LAMP** 11.33 12.13 13.07 15.44 21.4
*Threshold cycle.
**Time (min. s).TMPRSSS2 cells (Table 4). Viral isolation from Vero
cells required at least 500 copies of MERS-CoV, followed
by incubation at 37°C for 5 days. It contrast, although it
has been reported that TMPRSS2 enhances the entry and
fusion formation of MERS-CoV [31,32], Vero/TMPRSS2
cells exhibited syncytium formation with 23.2 copies of
MERS-CoV within 2 days of incubation.
The real-time RT-PCR was highly sensitive for MERS-
CoV, with upE and ORF1a assays capable of detecting as
few as 1.6 copies of MERS-CoV RNA. The RT-LAMP
was also able to detect viral RNA at levels as low as 0.7
copies, showing equivalence with the RT-PCR assay.
Viral isolation using Vero/TMPRSS2 cells was more sen-
sitive than that of Vero cells; however, genetic diagnostic
assays were consistently more sensitive than culture-
based methods. These data suggest that the RT-LAMP
assay is capable of detecting MERS-CoV with a sensiti-
vity similar to that of real-time-RT-PCR, even in clinical
specimens.
Next, clinical specimens previously diagnosed as other
respiratory pathogens were tested using the RT-LAMP
assay (Table 5). All reactions were negative, with no cross
reactivity for other respiratory viruses, indicating a high
degree of specificity for the RT-LAMP assay. Collectively,5 0.5 Negative control Sensitivity (copies)
2 36.6 > 40 > 40 1.6
31.8 > 40 > 40 3.4
4 22.33 > 30 > 30 3.4
b)
c)





































Figure 1 Sensitivity of the MERS-CoV RT-LAMP assay. a) Real-time amplification of MERS-CoV by RT-LAMP. Amplification of serially diluted
MERS-CoV RNA was measured in real-time using a Loopamp real-time turbidimeter (LA-320C). The differentiated value at each dilution was
calculated automatically, with values > 0.1 within 30 min (red line) considered positive. b, c) Detection of RT-LAMP amplicon by b) precipitation
of magnesium pyrophosphate and c) fluorescence under ultra violet light. For fluorescence detection, 1-μL Fluorescence Detection Reagent was
added to each reaction mixture. Fluorescent signals were detected under ultraviolet following completion of the amplification reaction. Successful
amplification could be detected as green fluorescent light.
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Table 3 Specificity of the RT-LAMP assay
Virus Titer/reaction Results (min)
Coronaviruses
MERS-CoV (EMC) 4 × 101 TCID50 14.24
HCoV 229E (VR-740) 3 × 103 PFU > 30
HCoV 229E (Sendai-H/1121/04) 5 × 103 PFU > 30
HCoV NL63 2.5 × 102 FFU > 30
HCoV OC43 (VR-1558) 1.3 × 103 TCID50 > 30
SARS-CoV (Frankfurt) 1 × 105 PFU > 30
Other Respiratory Viruses
RSV A (Long) 1 × 101 PFU > 30
RSV A (A2) 1 × 102 PFU > 30
RSV B (18537) 1 × 102 PFU > 30
RSV B (WV/14617/85) —* > 30
HMPV (Sendai-H/2404/2003) —* > 30
PIV 1 (C-35) 3 × 104 PFU > 30
PIV 3 (C-243) 5 × 103 PFU > 30
ADV 3 (G.B.) 2.5 × 102 TCID50 > 30
ADV 4 (RI-67) 1 × 102 TCID50 > 30
ADV 7 (Gomen) 2.5 × 102 TCID50 > 30
Flu A/California/7/2009 (H1N1pdm) 8 × 103 TCID50 > 30
Flu A/Victoria/210/2009 (H3N2) 2.5 × 106 TCID50 > 30
Flu B/Brisbane/60/2008 2.5 × 104 TCID50 > 30
*Titer unknown, but was confirmed by PCR.
PFU: plaque forming unit.
FFU: focus forming unit.
TCID50: 50% tissue culture infectious dose.
Table 5 Detection of MERS-CoV using clinical specimens
diagnosed as other respiratory viral infections
Diagnosed pathogen Results (min)
Positive control
*MERS-CoV (104 copies) 9.00
Coronaviruses
HCoV OC43 > 30
HCoV NL63 > 30
HCoV HKU1 > 30
Other Respiratory viruses
RSV A > 30
RSV B > 30
HMPV > 30
PIV 1 > 30
PIV 2 > 30
PIV 3 > 30
PIV 4 > 30
Rhinovirus > 30
Bocavirus > 30
Flu A H1 (Russian) > 30
Flu A H1 (2009 pdm) > 30
Flu A H3 > 30
Flu B (Yamagata) > 30
Flu B (Victoria) > 30
Flu C > 30
Measles virus > 30
Rubella virus > 30
*Synthesized RNA obtained from N protein region.
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is useful for epidemiological surveillance in suspected cli-
nical cases.
RT-LAMP validation for mismatched sequences
The primer set was constructed based on the conserved
region of the nucleocapsid protein sequence of the EMC
isolate of MERS-CoV (GenBank accession no JX869059.2).Table 4 Detection of MERS-CoV diluted with medium contain
Copies/50 μL 500,000 50,000 5000 500 50 5
Virus isolation*
Vero 6/6 6/6 6/6 3/6 0/6 0/6
Vero/TMPRSS2 6/6 6/6 6/6 6/6 5/6 0/6
Copies/reaction 50,000 5000 500 50 5 0.5
Real-time RT-PCR**
upE 22.0 25.3 28.7 32.3 33.2 > 40
ORF1a 21.9 25.2 28.5 32.2 32.5 > 40
RT-LAMP*** 11.00 11.16 12.18 13.48 18.04 23.12
*Positive number/tested number.
**Threshold cycle.
***Time (min. s).The number of sequences deposited in GenBank is
increasing, and this region of MERS-CoV exhibits sev-
eral sequences variation. Therefore, the primer sequences
were checked against the available MERS-CoV sequences.
Eighty-one MERS-CoV nucleocapsid sequences were col-
lected from GenBank, along with seven other sequencesing pharyngeal swabs
0.5 Negative control Sensitivity (copies) Time required
0/6 0/6 500 5 d
0/6 0/6 23.2 2 d
0.05
> 40 > 40 1.6 2 hr
> 40 > 40 1.6 2 hr
> 30 > 30 0.7 30 min
Figure 2 (See legend on next page.)
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Figure 2 Nucleotide mismatches in the MERS-CoV sequences. The MERS-CoV sequences that have mismatches with the RT-LAMP primer sets
were identified in an alignment based on the sequence of the EMC isolate (JX869059.2). The positions of six essential regions (F3, F2, F1, B3, B2,
and B1) and loop primers (LF and LB) are indicated. The accession numbers of the MERS-CoV sequences used in the alignment were as follows:
JX869059, KJ782550, KJ650098, KJ713295, KJ713296, KJ829365, KJ156905, KJ156883, KJ156944, KJ556336, KF958702, KF917527, KJ477102, KJ813439
and KF961221. Seven MERS-CoV sequences available online (England2, Jeddah_2014_C7149, C7569, C7770, C8826, C9055 and C9355) were also
used. The alignment was performed using GeneDoc ver. 2.7 (http://www.nrbsc.org/gfx/genedoc/).
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C7569, C7770, C8826, C9055, and C9355]. An align-
ment was constructed using the EMC isolate and mis-
matched sequences (Figure 2). The RT-LAMP primers
matched most of the 88 sequences. Primers B3 and LF
matched them completely. Primer F3 had one nucleo-
tide mismatch for two sequences. Primer LB had one
nucleotide mismatch for one sequence and had another
mismatch for two sequences. Primer BIP had one nu-
cleotide mismatch in B1 region of one sequence and
had another mismatch in the B2 region of five sequences.
Primer FIP had a one-nucleotide mismatch in the F1
region of 11 sequences (Table 1). The efficiency of RT-
LAMP for these mismatched sequences was evaluated
using an RNA template transcribed from a 1242-bp of
PCR amplicon from the nucleocapsid gene sequence of
MERS-CoV (Table 6). The sensitivity of RT-LAMP using
the RNA control template of the EMC isolate was 15.8
copies and tended to be lower than that using viral RNA
as the template. This might be caused by a difference in
RT efficiency or the secondary structure of RNA due to
the difference in length. The mismatches in the F3, F2, B1,
and LB region did not markedly affect the amplification
efficiency, and the sensitivity was equal to or twice that
of the EMC isolate. The mismatch in the B2 region
affected amplification slightly, and showed a fivefold
decrease in the sensitivity (73.4 copies). This mismatch
in B2 was seen in 5 sequences (KJ156883, KJ156944,
KF556336, KF958702, and KF917527) of the 88 MERS-
CoV sequences checked in this study. Nevertheless, theseTable 6 Evaluation of RT-LAMP amplification using mismatch
Accession Name
JX869059 EMC
Representative sequence Nucleotide position*
England2 28862







*Based on EMC isolate (JX869059.2).results suggest that the RT-LAMP primer set facilitates
amplification of the remaining 83 sequences to the same
level as the EMC isolate.
Discussion
As described above, definitive MERS-CoV diagnosis
requires amplification of at least two different virus-
specific genomic targets according to the case definition
reported on 3 July 2013 by the WHO. However, only two
real-time RT-PCR targets, upE and ORF1a, are currently
available for MERS-CoV detection with high specificity
and sensitivity [14,15]. Indeed, two previous cases repor-
ted by the Italian government had to be reclassified as
probable MERS-CoV infections, as they were unable to
fulfill these criteria (WHO, GAR, MERS-CoV summary
and literature update – as of 20 September 2013, http://
www.who.int/csr/disease/coronavirus_infections/update_
20130920/en/index.html). Additional sensitive and spe-
cific genetic diagnostic methods are therefore needed to
provide reliable MERS-CoV diagnoses.
This study describes a novel genetic diagnostic method
for MERS-CoV based on the RT-LAMP assay, with a
sensitivity and specificity equal to that of the upE and
ORF1a RT-PCR assays. This assay was also able to detect
MERS-CoV RNA in experimentally obtained nasopharyn-
geal swabs, and never showed cross reactivity to other re-
spiratory viruses, even in the case of clinical specimens.
The RT-LAMP method requires only a single tem-
perature for amplification, with results usually available
in less than 1 h by observing magnesium pyrophosphateed sequences
Sensitivity (copies)
15.8
Substitution Region in primer Sensitivity (copies)
C to T F3 7.3
C to T F3 15.8
T to C FIP (F2)
T to C FIP (F2) 34.1
T to C BIP (B1) 15.8
G to T BIP (B2) 73.4
C to T LB 39.7
C to T LB 7.3
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[21,22]. Although RT-LAMP amplification can be moni-
tored in real-time using a turbidimeter [23], the assay
can also be performed using basic laboratory equip-
ment, such as a heat block and water bath. The method
has been validated using various respiratory viruses, as
well as more diverse pathogens, such as bacteria [33-35],
protozoa [36-38], and parasites [39,40]. Furthermore, the
reagents necessary to perform RT-LAMP are commer-
cially available. Recently, Abd El Wahed et al., reported a
genetic diagnostic method for MERS-CoV based on re-
verse transcription isothermal recombinase polymerase
amplification (RT-PPA) assay. The method is highly sensi-
tive and can detect 10 copies of virus RNA within 3
to 7 minutes. Therefore, it is useful for the diagnosis of
MERS-CoV as well. However, RT-RPA requires a specific
tubescanner for detection. By contrast, the RT-LAMP
assay enables detection of amplicons by observing a mag-
nesium pyrophosphate precipitate or fluorescence signals
with the naked eye with no requirement for any spe-
cialized instruments. Taken together, the specificity and
sensitivity of the RT-LAMP assay described here, in com-
bination with its accessibility and ease of use, make this
assay a valuable tool for the diagnosis and epidemiologic
surveillance of human MERS-CoV infection, especially for
field use.
The primer sets described in this study matched to
most of the available sequences. However, several se-
quences had mismatches with the primers. The effect of
these mismatches on the RT-LAMP efficiency was evalu-
ated using a synthesized control RNA template: most of
the mismatches did not affect the amplification effi-
ciency of RT-LAMP. However, the substitution in B2
region of the primer, namely, a G to T substitution at
position 29018 in the nucleocapsid gene sequence of the
EMC isolate, was present in five MERS-CoV sequences
and caused a slight decrease in sensitivity. Of the five
sequences, KJ156883 (Asir_1_2013) belongs to the
Buraidah_1 clade, and is the only sequence in this
clade with such a substitution [41]. The other sequences
(KJ156944, Riyadh_5_2013; KJ556336, Jeddah_1_2013;
KF958702, Jeddah_human1; KF917527, Jeddah_Camel1)
belong to the Riyadh_3 clade [42,43]; none of the other se-
quences in this clade have a substitution according to the
alignment analysis. Therefore, the substitution does not
represent a major population in this clade. Although it is
important to improve the primers to increase their sensi-
tivity for sequences in the Riyadh_3 clade by using mixed
bases, the results of this study suggest that the RT-LAMP
primer is useful for detecting the majority of the prevalent
MERS-CoV strains.
The success rate of MERS-CoV detection is dependent
on the collection of clinical specimens. Drosten et al.,
reported that up to 106 copies/mL of MERS-CoV RNAare present in lower respiratory tract specimens, such as
tracheobronchial secretions, and bronchoalveolar lavage.
In contrast, only small amounts of viral RNAs were de-
tected in upper respiratory tract specimens and other
tissue [44]. The RT-LAMP primers described here were
designed based upon the nucleocapsid protein sequence
of MERS-CoV, due to the unique coronaviral replication
system. Although coronaviruses generate subgenomic
mRNAs to produce each viral protein, all subgenomic
mRNAs contain nucleoprotein sequences, as they are lo-
cated on the 3′end of the coronavirus genome [45-47].
This implies that the RT-LAMP procedure described
here will exhibit a high degree of sensitivity for speci-
mens containing cellular components.Conclusions
This study developed a RT-LAMP assay for the MERS-
CoV, which was capable of detecting as few as 3.4 copies
of MERS-CoV RNA, and was highly specific, with no
cross-reaction with other respiratory viruses. These re-
sults suggest that the RT-LAMP assay described here is
a useful tool for the diagnosis and epidemiologic surveil-
lance of human MERS-CoV infections.Abbreviations
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